miR-24-2 targets Akt and inhibits cell survival, EMT, and tumour growth in triple-negative breast cancer
Biochemical and Biophysical Research Communications · 2025
DOI: 10.1016/j.bbrc.2025.152182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2025. Verfasst von Mansoor Ali und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India. Hauptthemen laut MEDLINE: MicroRNAs, Proto-Oncogene Proteins c-akt, Triple Negative Breast Neoplasms, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: DBT, Indian Council of Medical Research, University Grants Commission.
Abstract (Originalsprache)
BACKGROUND: Breast cancer is one of the most common types of cancer in the world, and triple-negative breast cancer (TNBC) is an extremely aggressive subtype. This study aimed to investigate the efficacy and mechanisms of miR-24-2 against TNBC. METHODS: MDA-MB-231 (TNBC), HEK293T and HEK293 cells were used for various assays including cell viability and proliferation, cell migration, and invasion. RT-PCR, immunoblotting, acridine orange-ethidium bromide and DCFDA assays, tumour xenograft, H&E and IHC methods were employed in the study. RESULTS: miR-24-2 overexpression induced cell death and inhibited clonogenic potential. It also reduced the expression of Slug, Twist1, and Vimentin and inhibited cell invasion and migration. miR-24-2 enhanced apoptosis, ROS production, and expression of pH2A.X (S139) while decreased Chk1, Chk2, and Rad51. miR-24-2 inhibited survival signaling by downregulating Akt, Erk1/2, Bcl-2, and cytochrome c (mitochondrial), and enhancing Bax, cytochrome c (cytosolic), and cleaved-caspase 3. miR-24-2 binds to the coding sequence (CDS) of Akt which was validated at mRNA and protein expression levels. Further, miR-24-2 strongly reduced TNBC tumour volume (58 %, p < 0.01) and weight (54 %, p < 0.001) during 20 days. Tumour immunohistochemistry showed that miR-24-2 decreased proliferation and increased apoptosis. Moreover, increased Bax/Bcl-2 ratio and decreased expression of Akt, PCNA, Chk1, Chk2, and Rad51 by miR-24-2 were found in tumours, validating the findings of in vitro and in vivo tumour models. CONCLUSION: Overall, this study finds that miR-24-2 directly targets Akt and plays a significant role in TNBC as a key mechanism for its growth, survival, and progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
- Cancer Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India; Department of Biochemistry, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India.
- Cancer Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India; Special Centre for Systems Medicine, Jawaharlal Nehru University, New Delhi, India; Department of Pharmaceutical Science…
Förderung
- DBT
- Indian Council of Medical Research
- University Grants Commission
- Department of Science and Technology, Ministry of Science and Technology, India
Zitieren
APA
Ali, M., Singh, N., Yadav, M., Nayak, S., Bamezai, R. N. K., & Singh, R. P. (2025). miR-24-2 targets Akt and inhibits cell survival, EMT, and tumour growth in triple-negative breast cancer. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2025.152182
Vancouver
Ali M, Singh N, Yadav M, Nayak S, Bamezai RNK, Singh RP. miR-24-2 targets Akt and inhibits cell survival, EMT, and tumour growth in triple-negative breast cancer. Biochemical and Biophysical Research Communications. 2025. doi:10.1016/j.bbrc.2025.152182
BibTeX
@article{Ali2025,
author = {Ali, Mansoor and Singh, Navneendra and Yadav, Monika and Nayak, Satyabrata and Bamezai, Rameshwar N K and Singh, Rana P},
title = {miR-24-2 targets Akt and inhibits cell survival, EMT, and tumour growth in triple-negative breast cancer},
journal = {Biochemical and Biophysical Research Communications},
year = {2025},
doi = {10.1016/j.bbrc.2025.152182}
}
EUVIMED